Fig. 14
From: Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker
Validation analysis of KRT6A in LUAD clinical cohort. (A–D) Based on the clinical data sets of TCGA and GEO, the expression of KRT6A in LUAD and its correlation with disease diagnosis and patient prognosis were verified. (E) Representative immunohistochemistry images of KRT6A in tumor tissues and adjacent normal tissues of LUAD patients. (F–I) GSEA analysis of KRT6A in the LUAD cohort was performed thru the LinkedOmics database, and the bar charts show the GO-BP, GO-CC, GO-MF and KEGG analysis results related to the KRT6A gene, respectively. *, **, and *** represent P < 0.05, P < 0.01, and P < 0.001, respectively. Generally, P < 0.05 and/or FDR ≤ 0.05 were considered statistically significant.
